We are happy and proud to finally announce that CarboHyde won a 2024-1.2.7-EUROSTARS-2025-00007 grant and shall receive ~190,000k Eur to develop a novel cyclodextrin-based Alzheimer asset.
The novel mechanism of action focuses on cholesterol modulation in this neurodegenerative disease and will aim to complete most IND-enabling preclinical studies so that regulatory filings and clinical studies can begin shortly.
This advanced, practice-oriented session explores how cyclodextrins enable safe, effective injectable formulations across small molecules and biologics, including protein therapeutics and vaccines.
The Masterclass blends scientific fundamentals, hands-on formulation strategy, and real-world case studies, addressing both opportunities and limitations while highlighting emerging directions in the field.
What You’ll Learn Parenteral-grade cyclodextrins: selection criteria, quality attributes, and regulatory expectations Formulation development & optimization: solubility enhancement, stability, compatibility, and excipient interactions Biologics-focused insights: protein stabilization, aggregation control, vaccine formulation considerations Small-molecule injectables: complexation strategies, safety margins, and performance trade-offs Case studies: successes, pitfalls, and decision frameworks from development to scale-up Limitations & risk management: toxicity thresholds, dosing constraints, and formulation boundaries What’s next: novel derivatives, new indications, and innovation pathways
Who Should Attend? This Masterclass is designed for professionals working in or transitioning to parenteral drug development, including:
Formulation Scientists & R&D Leaders (small molecules and biologics) CMC, Pharmaceutical Development & Technical Operations Teams Vaccine Developers & Protein Scientists Drug Delivery & Enabling Technology Specialists Regulatory Affairs & Quality Professionals Project Managers & Decision-Makers evaluating injectable formulation strategies
Why You’ll Benefit Practical, decision-ready knowledge: Move beyond theory to actionable formulation strategies Cross-modality perspective: Understand how cyclodextrins behave differently with proteins, vaccines, and small molecules Risk-aware development: Learn where cyclodextrins add value—and where they may not Accelerated development timelines: Apply proven approaches to reduce iteration cycles Future-proof insights: Stay ahead of regulatory, technological, and clinical trends
Format & Experience Live, expert-led online session Structured learning + applied examples Interactive discussion and Q&A Comprehensive takeaways you can apply immediately in development programs
Key Topics at a Glance Parenteral excipient requirements Cyclodextrin–API and cyclodextrin–protein interactions Stability, safety, and scalability Clinical and commercial considerations Innovation beyond current standards
Who It’s For (In One Line) If you develop, evaluate, or make decisions about injectable formulations—from early R&D to late-stage programs—this Masterclass is built for you.
We are the proudest, when students we mentor flourish and grow.
Fahad Khan Tareen, PhD spent a short time this year at CarboHyde, so we dont take the merits for his excellent science, but hope the insights we gave can contibute to his career.
Congratulations on your PhD!
We wish you the best, and dont dare to move away from cyclodextrins 🙂
We are happy and proud to finally announce that CarboHyde won a 2024-1.2.7-EUROSTARS-2025-00007 grant and shall receive ~190,000k Eur to develop a novel cyclodextrin-based Alzheimer asset.
The novel mechanism of action focuses on cholesterol modulation in this neurodegenerative disease and will aim to complete most IND enabling preclinical studies so that regulatory filings and clinical studies can begin shortly.
This year’s journey of co-authoring multiple research papers (8), we feel proud and humbled by the collective effort and trust from our collaborators.
This effort has also been recognized when Milo Malanga PhD received the 1st Thorseinn Loftsson award for cyclodextrin research recently.
Our work — from advancing molecular understanding of cyclodextrin host–guest systems and enantioselective complexation, to proposing a clearer nomenclature for modified cyclodextrins, and exploring innovative drug delivery strategies — contributes to practical building blocks for pharmaceutical science.
Cyclodextrins and their derivatives remain versatile tools in enhancing drug solubility, stability, and delivery performance, and clearer frameworks and analytical insights help accelerate their adoption in real-world drug development.
Science is a shared effort — these studies represent many minds thinking together to address complex challenges in drug formulation and molecular design.
We are thankful to our co-authors, reviewers, and supporting institutions for making this possible.
Recently I had the chance to sit down with Louise Jefferies on her podcast Speaking up in English at Work for Introverts – and it turned into one of the most honest conversations I’ve had about science, communication, and the fears many of us quietly carry.
My main message was simple: Scientists are doing extraordinary work behind the scenes… but far too much of it never reaches the people who need it.
In the episode, we talked about something I see every day in our field: most scientists stay silent — not because they lack expertise, but because they doubt whether their voice matters. And that silence costs the industry more than we realise.
We unpacked a lot, including • why publishing papers is no longer enough • how misinformation fills the void when experts hold back • the visibility challenges introverts and multilingual scientists face • the fear of posting, presenting, or speaking up (and why our imagined catastrophes almost never happen) • why LinkedIn is actually one of the safest, kindest spaces to start sharing • and how having a purpose makes fear feel a lot smaller
If there’s one thing I hope listeners take away, it’s this: Your work can influence decisions, shape policy, and move our field forward — but only if your voice is heard.
You don’t need to be louder. You don’t need to perform. You just need to stop hiding expertise that genuinely matters.
If you’ve ever hesitated to post, present, or speak up in a meeting, this conversation might be exactly what you need.
Moga, Punjab, India – ISF College of Pharmacy (An Autonomous College), Moga, is proud to announce that it will host the 22nd International Cyclodextrin Symposium (ICS22) from October 22-26, 2026. This marks a historic milestone as the first time this prestigious international symposium is being held in India.
The symposium, themed “Integrating Cyclodextrin and AI Techniques for Next-Generation Novel Drug Delivery Systems,” will bring together more than 500 leading scientists, researchers, academicians, and industry professionals from over 40 countries to discuss groundbreaking advances in cyclodextrin chemistry and its revolutionary applications in pharmaceutical sciences.
The symposium will cover diverse topics including: # Cyclodextrin chemistry and characterization # Novel drug delivery systems # AI and machine learning in pharmaceutical formulation # Nanotechnology applications # Industrial perspectives and commercialization # Regulatory aspects and quality control # Clinical applications and case studies
Before Christmas, we presented the “exam” of the cyclodextrin masterclasses. The contestants competed online, facing 30 questions about cyclodextrins to find out who is the king of cyclodextrins.
Not only were the event and all the masterclasses fun to deliver, but Shima’s message also warmed our hearts dearly:
“I would like to sincerely thank you, for the excellent masterclasses and for all the support you provide. The sessions were extremely valuable and truly enhanced my understanding of cyclodextrins.
I also wanted to share that I placed first in the online competition . It was a great experience, and it would not have been possible without the quality of the training and materials you provided.
Thank you again for your dedication, knowledge sharing, and continuous support. It is greatly appreciated.”
Join us at the 2nd Bicyclos HEurope International School & Workshop (Feb 18–20, Seville) for expert seminars and hands-on training on cyclodextrin applications, AI-driven molecular design, IP, and scientific communication—tailored for PhD candidates, early postdocs, and industry R&I professionals.
Registration is mandatory and open until Jan 15, 2026—secure your spot to learn from leading experts, expand your network, and explore sustainable, next-generation approaches in cyclodextrin research.
?️ Dates
Feb 18–19: Expert seminars on cyclodextrin applications (from healthcare to environmental sciences)
Feb 19–20: Practical sessions on (i) research project preparation, (ii) AI for molecular design, data analysis & scientific writing, (iii) IP protection, and (iv) scientific communication & broadcasting
? Registration
Mandatory (Bicyclos registration form)
Free for Bicyclos staff
€200 for external participants (includes event access, lunches Feb 18–19, and coffee breaks Feb 18–20)
Deadline:Jan 15, 2026
Industry:exhibition space available on request
? Venue Institute of Chemical Research (IIQ, CSIC – University of Seville), well connected to the city center (bus/taxi).
? Accommodation tip Early booking recommended; Hotel Exe Macarena is suggested for convenient access and good value.
The School organised by CSIC, Sevilla, is aimed primarily at PhD candidates and early postdoctoral researchers, offering training on various aspects of cyclodextrin pharmacology, and biomedical applications, all within the broader context of sustainability.
In this context, advanced models in substitution of animal studies for drug development will be discussed. Scientific Masterclasses by external experts will be scheduled on the first two days. Extra classes in soft skills are planned on the third day. Check out the programme:
A key objective of the School is to foster networking opportunities among participants.
1. What Cyclodextrin Brings to Adenoviral Formulations Hydroxypropyl-β-cyclodextrin (HPβCD) helps stabilize adenoviral vectors by creating a protective environment around the particles, reducing aggregation and degradation.
2. Supporting Complex Purification Workflows After multi-step purification—such as tangential flow filtration and two-step anion exchange chromatography—cyclodextrin helps maintain the integrity of the highly purified recombinant adenovirus.
3. Enhancing Stability in the Final Drug Product In the final formulation buffer, HPβCD works alongside excipients like glycerol, sucrose, and polysorbate 80 to improve thermal and storage stability, helping the therapy remain potent over time.
4. Enabling Reliable Delivery of Gene Therapies By protecting the viral capsid and improving overall formulation robustness, cyclodextrin plays a quiet but vital role in ensuring adenoviral gene therapies reach patients in their intended, effective form.
